LY3023414 inhibits both osteogenesis and osteoclastogenesis through the PI3K/Akt/GSK3 signalling pathway

The PI3K/AKT/mTOR signaling pathway in osteoarthritis: a narrative review

(2020) K. Sun et al.   OSTEOARTHRITIS AND CARTILAGE

PI3K/Akt/mTOR inhibitors in cancer: At the bench and bedside

(2019) Ali S. Alzahrani   SEMINARS IN CANCER BIOLOGY

Angelica polysaccharide promotes proliferation and osteoblast differentiation of mesenchymal stem cells by regulation of long non-coding RNA H19

(2019) Xiaoyan Xie et al.   Bone & Joint Research

Phase 2 study of LY3023414 in patients with advanced endometrial cancer harboring activating mutations in the PI3K pathway

(2019) Maria M. Rubinstein et al.   CANCER

Primer3_masker: integrating masking of template sequence with primer design software

(2018) Triinu Kõressaar et al.   BIOINFORMATICS

A First-in-Human Phase 1 Study of LY3023414, an Oral PI3K/mTOR Dual Inhibitor, in Patients with Advanced Cancer

(2018) Johanna C. Bendell et al.   CLINICAL CANCER RESEARCH

Multidisciplinary management of oculo-auriculo-vertebral spectrum

(2018) Angela Vong et al.   Current Opinion in Otolaryngology & Head and Neck Surgery

C/ebpα controls osteoclast terminal differentiation, activation, function, and postnatal bone homeostasis through direct regulation of Nfatc1

(2018) Wei Chen et al.   JOURNAL OF PATHOLOGY

PI3K/AKT/mTOR pathway in multiple myeloma: from basic biology to clinical promise

(2018) Vijay Ramakrishnan et al.   LEUKEMIA & LYMPHOMA

Dual PI3K/mTOR Inhibition in Colorectal Cancers with APC and PIK3CA Mutations

(2017) Tyler M. Foley et al.   MOLECULAR CANCER RESEARCH

Gα13 negatively controls osteoclastogenesis through inhibition of the Akt-GSK3β-NFATc1 signalling pathway

(2017) Mengrui Wu et al.   Nature Communications

Autophagy inhibition sensitizes LY3023414-induced anti-glioma cell activity in vitro and in vivo

(2017) Lan Zheng et al.   Oncotarget

Enhanced Wnt signaling improves bone mass and strength, but not brittleness, in the Col1a1 +/mov13 mouse model of type I Osteogenesis Imperfecta

(2016) Christina M. Jacobsen et al.   BONE

Characterization of LY3023414, a Novel PI3K/mTOR Dual Inhibitor Eliciting Transient Target Modulation to Impede Tumor Growth

(2016) M. C. Smith et al.   MOLECULAR CANCER THERAPEUTICS

PI3K/Akt signaling in osteosarcoma

(2015) Jian Zhang et al.   CLINICA CHIMICA ACTA

The WNT system: background and its role in bone

(2015) U. H. Lerner et al.   JOURNAL OF INTERNAL MEDICINE

The AKT genes and their roles in various disorders

(2013) M. Michael Cohen   AMERICAN JOURNAL OF MEDICAL GENETICS PART A

Crosstalk between tyrosine kinase receptors, GSK3 and BMP2 signaling during osteoblastic differentiation of human mesenchymal stem cells

(2013) Emmanuel Biver et al.   MOLECULAR AND CELLULAR ENDOCRINOLOGY

Primer3—new capabilities and interfaces

(2012) Andreas Untergasser et al.   NUCLEIC ACIDS RESEARCH

Akt signalling in health and disease

(2011) Ingeborg Hers et al.   CELLULAR SIGNALLING

Akt Induces Osteoclast Differentiation through Regulating the GSK3 /NFATc1 Signaling Cascade

(2011) J. B. Moon et al.   JOURNAL OF IMMUNOLOGY

Akt promotes BMP2-mediated osteoblast differentiation and bone development

(2009) A. Mukherjee et al.   JOURNAL OF CELL SCIENCE